Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.20

+0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOEBT1 who wrote (11160)	11/15/1997 2:22:00 PM
From: Henry Niman	Read Replies (1) of 32384

JOEBT1, The LGND lawsuit against PFE was settled outside of court in LGND's favor. PFE agreed to pay LGND milestones on Droloxifene (some of which has already been paid) and to pay a royalty of 1% of gross worldwide sales of Droloxifene for breast cancer. If Droloxifene is approved for other indications (such as osteoporosis), the royalty rate will go up to 3% of sales for all indications, including breast cancer. The royalty rate on CP-366,156 is 6%. All other alliances that LGND has includes double digit royalty rates. As far as the psoriasis trial is concerned, I think that Phase II is just about finished. Clinically, LGND is set to start Phase III. However, they have many promising trials and I'm not sure where psoriasis is on their priority list (Phase III trials are very expensive).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next